Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/33075
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOlver, I.en
dc.contributor.authorVadas, M.en
dc.contributor.authorLopez, A.en
dc.contributor.authorKeefe, D.en
dc.contributor.authorTaylor, A.en
dc.contributor.authorBrown, M.en
dc.contributor.authorTo, L.en
dc.date.issued2000en
dc.identifier.citationProceedings of ASCO - Volume 19 2000, 2000 / pp.475aen
dc.identifier.urihttp://hdl.handle.net/2440/33075-
dc.language.isoenen
dc.publisherAmerican Society of Clinical Oncologyen
dc.titleA phase 1 study of the GM-CSF antagonist E21Ren
dc.typeConference itemen
dc.identifier.rmid0001002892en
dc.contributor.conferenceASCO - Volume 19 2000en
dc.publisher.placeUSAen
dc.identifier.pubid62467-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidOlver, I. [0000-0001-5478-1576]en
dc.identifier.orcidKeefe, D. [0000-0001-9377-431X]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.